Abstract Library

#4256 Epigenetic prediction of aging and metabolic traits provides insight into tumor biology in multi-focal ileal neuroendocrine tumors

Introduction: Approximately half of small intestinal neuroendocrine tumors (siNETs) are multifocal, and recent investigations into the genetic architecture of these tumors have found that they are not clonal. Due to the low mutational rate and slow growing nature of these small tumors, the ‘timing’ of the development of individual tumors has not been possible.

Conference:

Presenting Author:

Authors: Webster A, Makinen N, Ecker S, Beck S, Nakakura E,

Keywords: DNA methylation, Epigenetics, Multifocal Ileal Neuroendocrine Tumor, Multifocal Small Instestinal NET, Metabolic Traits,

#4075 A phase II study of Lenvatinib and Everolimus in advanced well-differentiated extra pancreatic neuroendocrine tumors

Introduction: Data suggest that combined inhibition of VEGF and FGF is an effective antiangiogenic strategy and that concomitant inhibition of the mTOR pathway may be further synergistic.

Conference:

Presenting Author: Dasari A

Authors: Dasari A, Qiao W, Halperin D, Stanietzky N, Surabhi V,

Keywords: Extrapancreatic NET, Lenvatinib, Everolimus, Phase II,

#3976 Radiologic tumor border status can further stratify patients with pancreatic neuroendocrine tumor

Introduction: Recently, pattern-based classifications of the tumor border of pancreatic neuroendocrine tumor (PanNET) have been attempted by independent groups for patient stratification, which are only available in the post-operative setting.

Conference:

Presenting Author: Ahn B

Authors: Ahn B, Park H, Kim H, Hong S,

Keywords: pancreas, neuroendocrine tumor, pathologic tumor border, radiologic tumor border, survival, prognosis,

#3959 Sortilin: A novel marker and potential therapeutic target for functional neuroendocrine tumors

Introduction: A subset of neuroendocrine tumors (NETs) causes a hormone-related disease (functional syndrome); e.g. carcinoid syndrome due to over-secretion of mainly serotonin. Notably, on a molecular level, what distinguishes this subset of functional NETs from nonfunctional tumors is unknown. Furthermore, accurate models of functional NETs are missing. Sortilin, a widely expressed transmembrane receptor, is expressed in many cancer cells, including NETs, and is involved in secretion processes.

Conference:

Presenting Author: Bolduan F

Authors: Bolduan F, Wetzel A, Giesecke Y, Eichhorn I, Alenina N,

Keywords: Neuroendocrine tumor, Functional syndrome, Carcinoid syndrome, Serotonin, Sortilin, Organoids, Enteroendocrine cells,

#3848 LITESPARK-015 cohort B1 – A phase 2 open-label study of Belzutifan (a HIF-2α inhibitor) monotherapy in patients with von Hippel-Lindau (VHL) disease–associated tumors

Introduction: Patients (pts) with von Hippel-Lindau (VHL) disease need novel targeted therapies. Hypoxia-inducible factor 2α (HIF-2α) is a key oncogenic driver in VHL disease. Belzutifan (MK-6482), a HIF-2α inhibitor, has shown antitumor activity in pts with advanced renal cell carcinoma (RCC) and pancreatic neuroendocrine tumors (pNETs); more data are needed in VHL disease–associated localized tumors.

Conference:

Presenting Author:

Authors: Walter T, Gong K, Nakamura E, Iliopoulos O, Jimenez C,

Keywords: von Hippel-Lindau disease, belzutifan, MK-6482,